SLC5A2 and chronic kidney disease: However, given the association between CKD progression and CVD, event rates for kidney outcomes in participants with CKD and T2D randomized to placebo in addition to maximally tolerated/clinically appropriate RAS blockade in contemporary SGLT2 inhibitor trials provide insight on expected outcomes with ACEis and ARBs [65].